-
AMC-1001
Anti-cancer drugs market size
The anti-cancer drug market is poised for rapid expansion, with a projected surge from $143 billion in 2022 to an estimated $377 billion by 2027, boasting an annual growth rate of 13–16%.
Expected to witness the launch of over 100 new drugs in the next 5 years, including cutting-edge cell and gene therapies and immunotherapies, this growth is fueled by the escalating number of cancer cases worldwide.
The introduction of targeted anti-cancer drugs, while enhancing treatment efficacy, also contributes to the upward trajectory of treatment costs.(Source: Global Use of Medicines 2023, outlook to 2027, IQVIA institute, 2023) 
AMC Science is developing various antibody treatments that use the SurvivAb platform to separate antibodies from survivors of solid cancer patients
and selectively bind them to cell membrane antigens of cancer cells.
AMC-1001 : Development of Anti-cancer Antibodies through the SurvivAb Platform
-
AMC-2001
Ophthalmic Disease Treatment Market Size
The market for ophthalmic disease therapeutics is set for substantial growth, projecting an increase from $33.5 billion in 2021 to $65.6 billion by 2030, with an average annual growth rate of 7.7%. Key drivers of this expansion include the continual introduction of ophthalmic drugs drugs through robust research and development (R&D) efforts, strategic initiatives tailored to meet the evolving needs of ophthalmologists, and the increasing prevalence of vision and visual impairment.
According to a World Health Organization (WHO) report in October 2021, 2.2 billion patients suffer from visual impairment, of which 1 billion cases can be treated with ophthalmic drug use.
The increase in the ophthalmic drug pipeline is expected to further expand the market.(Source: Million Insights, Ophthalmic Drugs Market Size Worth $65.6 Billion By 2030, 2022) 
Eye disease caused by aging is the most common cause of blindness and causes serious poor quality of life.
Existing approaches predominantly involve laser therapy and drug injections into the vitreous, yet issues persist, including treatment resistance and a lack of early prevention models.
AMC Sciences is pioneering a new class of drugs based on novel mechanisms to overcome the limitations of existing therapies for age-related eye diseases.
-
AMC-3001
Market Size for Immunological Diseases
The market for immunology-related diseases is expected to grow from $143 billion in 2022 to $177 billion in 2027, with an average annual growth rate of 3–6%.
Within the immunotherapy landscape, encompassing atopic and asthma treatments, a parallel growth trajectory of will 3–6% is also anticipated.
Notably, the expiration of patents for many immunotherapies, such as Humira, is expected to lead to significant shifts in the immunotherapy market, including increased competition.(Source: Global Use of Medicines 2023, outlook to 2027, IQVIA institute, 2023) 
Autoimmune diseases, characterized by the immune system erroneously attacking the body’s own tissues, encompass rare conditions such as lupus, rheumatoid arthritis, type 1 diabetes, Crohn's disease, and multiple sclerosis. Currently, a fundamental cure for autoimmune diseases remains elusive, creating a high demand for innovative drug development to address unmet medical needs. In response, AMC Sciences is at the forefront of developing novel drugs for the treatment of autoimmune diseases.
Leveraging human-derived proteins with anti-inflammatory effects, these drugs provide a safer and more effective treatment paradigm.
-
AMC-4001
Market Size of Pigmentation Disease-Related Treatments
The market size of pigmentary disorder therapeutics is poised for growth, projecting an average annual growth rate of 5.43% to ascend from $7.02 billion in 2023 to an estimated $9.15 billion in 2028.
Pigmentary disorders, characterized by alterations in melanin cell density or concentration, cause changes in skin pigmentation, and are categorized into hypopigmentation and hyperpigmentation.
Current treatment modalities include localized therapies, skin peeling, laser therapy, and phototherapy, tailored to diseases such as vitiligo, melasma, inflammatory hyperpigmentation, and others. However, there is a demand for more diverse therapeutic options. 
Human skin, subject to a lifetime of environmental stressors, relies on melanin as a critical photoprotective factor.
This pigment safeguards against potential damage caused by ultraviolet radiation and absorbs free radicals in the skin.
Recognizing the limitations of existing whitening agents and therapeutic approaches, AMC Sciences is actively developing novel drugs that can effectively treat excessive pigmentation and hypo-pigmentation by regulating melanin synthesis, presenting a breakthrough in the treatment landscape of pigmentary disorders.
